載入中
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
一般交易時段
US$0.63
+US$0.0198 · +3.24%
盤中時間採用ET。市場資料可能有所延遲。
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
日內區間
目前US$0.63
52週區間
目前US$0.63
盤中時間採用ET。市場資料可能有所延遲。
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
日內區間
目前US$0.63
52週區間
目前US$0.63
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 研究與開發 | 1029.26萬 USD | 1867.63萬 USD | 2170.83萬 USD | 1638.72萬 USD |
| 銷售、一般及管理費用 | 1220.27萬 USD | 648.45萬 USD | 326.55萬 USD | 381.96萬 USD |
| 營業費用 | 2249.53萬 USD | 2516.07萬 USD | 2497.38萬 USD | 2020.68萬 USD |
| 利息收入 | 28.77萬 USD | 22.23萬 USD | 35.27萬 USD | 2.7萬 USD |
| 利息支出 | 2.03萬 USD | −1.87萬 USD | 4.36萬 USD | 1.62萬 USD |
| 折舊和攤銷 | — | 2516.07萬 USD | 2497.38萬 USD | 2020.68萬 USD |
| 營業利益 | −2249.53萬 USD | −2516.07萬 USD | −2497.38萬 USD | −2020.68萬 USD |
| 淨利 | −2222.79萬 USD | −2728.53萬 USD | −2474.46萬 USD | −2015.94萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI43.68萬0.00%2.3兆 USD0.03%US$381.65-0.08%
Vanguard Extended Market ETFVXF16.12萬0.00%954億 USD0.05%US$234.02-0.42%
iShares Micro-Cap ETFIWC2.21萬0.00%13.17億 USD0.60%US$182.06-0.51%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM1萬0.01%1.17億 USD0.73%US$15.91-0.19%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
